Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Periodicals
J&J reached out to vaccine rivals to study blood clot risk, WSJ reports » 09:33
04/16/21
04/16
09:33
04/16/21
09:33
JNJ

Johnson & Johnson

$160.44 /

+0.49 (+0.31%)

, PFE

Pfizer

$37.61 /

+0.45 (+1.21%)

, MRNA

Moderna

$159.85 /

-0.25 (-0.16%)

, AZN

AstraZeneca

$50.84 /

+0.97 (+1.95%)

Johnson & Johnson…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

MRNA Moderna
$159.85 /

-0.25 (-0.16%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/13/21 Goldman Sachs
J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
PFE Pfizer
$37.61 /

+0.45 (+1.21%)

04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
04/09/21
Pfizer to host conference call
04/06/21 RBC Capital
Pfizer transferred with a Sector Perform at RBC Capital
MRNA Moderna
$159.85 /

-0.25 (-0.16%)

04/15/21 Piper Sandler
Moderna price target raised to $234 from $208 at Piper Sandler
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 Piper Sandler
Piper reiterates $208 target on Moderna after J&J Covid vaccine pause
04/07/21 Jefferies
Catalent pact with Moderna removes potential overhang, says Jefferies
AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/12/21
Fly Intel: Top five analyst downgrades
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
04/12/21 Argus
AstraZeneca downgraded to Hold from Buy at Argus
JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

MRNA Moderna
$159.85 /

-0.25 (-0.16%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

  • 19
    May
JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

MRNA Moderna
$159.85 /

-0.25 (-0.16%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

MRNA Moderna
$159.85 /

-0.25 (-0.16%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

JNJ Johnson & Johnson
$160.44 /

+0.49 (+0.31%)

PFE Pfizer
$37.61 /

+0.45 (+1.21%)

MRNA Moderna
$159.85 /

-0.25 (-0.16%)

AZN AstraZeneca
$50.84 /

+0.97 (+1.95%)

Yesterday
Hot Stocks
Schrodinger holder David Shaw sells 120.4K shares of common stock » 19:00
04/15/21
04/15
19:00
04/15/21
19:00
SDGR

Schrodinger

$78.44 /

+0.29 (+0.37%)

In a regulatory filing,…

In a regulatory filing, Schrodinger disclosed that David E. Shaw sold 120.4K shares of common stock on April 13th in a total transaction value of $9.29M.

ShowHide Related Items >><<
SDGR Schrodinger
$78.44 /

+0.29 (+0.37%)

SDGR Schrodinger
$78.44 /

+0.29 (+0.37%)

03/24/21 BMO Capital
Schrodinger price target lowered to $104 from $110 at BMO Capital
03/15/21 Jefferies
Schrodinger shares should recover on beats, discovery progress, says Jefferies
01/25/21 BMO Capital
Schrodinger price target raised to $117 from $97 at BMO Capital
11/23/20 BofA
BofA upgrades Schrodinger to Buy after 'major' collaboration announcement
SDGR Schrodinger
$78.44 /

+0.29 (+0.37%)

  • 13
    Aug
SDGR Schrodinger
$78.44 /

+0.29 (+0.37%)

SDGR Schrodinger
$78.44 /

+0.29 (+0.37%)

Recommendations
Moderna price target raised to $234 from $208 at Piper Sandler » 05:03
04/15/21
04/15
05:03
04/15/21
05:03
MRNA

Moderna

$160.10 /

+10.62 (+7.10%)

Piper Sandler analyst…

Piper Sandler analyst Edward Tenthoff raised the firm's price target on Moderna to $234 from $208 and reiterates an Overweight rating on the shares. The stock closed Wednesday up 7% to $160.03. The company's vaccine day yesterday focused on SARS-COV-2 vaccine mRNA-1273 with Phase III COVE data out to six months showing over 90% protection against COVID-19 and over 95% protection against severe infection, Tenthoff tells investors in a research note. The analyst continue to forecast mRNA-1273 revenues of $10.85B in 2021 and $15.75B in 2022. He sees future revenues from complete vaccination in the U.S., overseas vaccinations and U.S. boosters, noting that Covid-19 is "not going away." Further, Moderna is advancing a "rich pipeline" of mRNA medicines, adds Tenthoff.

ShowHide Related Items >><<
MRNA Moderna
$160.10 /

+10.62 (+7.10%)

MRNA Moderna
$160.10 /

+10.62 (+7.10%)

04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 Piper Sandler
Piper reiterates $208 target on Moderna after J&J Covid vaccine pause
04/07/21 Jefferies
Catalent pact with Moderna removes potential overhang, says Jefferies
03/15/21 Piper Sandler
Piper Sandler bullish on Moderna as first subject vaccinated in '1283 study
MRNA Moderna
$160.10 /

+10.62 (+7.10%)

  • 19
    May
MRNA Moderna
$160.10 /

+10.62 (+7.10%)

MRNA Moderna
$160.10 /

+10.62 (+7.10%)

MRNA Moderna
$160.10 /

+10.62 (+7.10%)

Wednesday
Periodicals
Top White House officials to discuss vaccine rollout with House, CNBC says » 17:41
04/14/21
04/14
17:41
04/14/21
17:41
JNJ

Johnson & Johnson

$159.95 /

+0.44 (+0.28%)

, PFE

Pfizer

$37.16 /

+0.01 (+0.03%)

, BNTX

BioNTech

$132.52 /

+3.11 (+2.40%)

, MRNA

Moderna

$160.10 /

+10.62 (+7.10%)

, SPX

S&P 500

/

+

, SPY

SPDR S&P 500 ETF Trust

$411.49 /

-1.34 (-0.32%)

The House coronavirus…

The House coronavirus subcommittee will hear Thursday from three top White House health officials about the U.S.' efforts to increase vaccinations as COVID-19 cases, including those from new variants, are rising, CNBC's Kevin Breuninger reports. The hearing is set to start at 10:30 am ET and will be livestreamed, Breuninger notes. The move comes two days after dozens of states halted the administration of Johnson & Johnson's (JNJ) single dose vaccine in response to the FDA's recommendation that those shots be paused while it looks into cases of women who took the vaccine and developed a rare blood-clotting disorder, the author says. The Fly notes that the U.S. has so far approved COVID-19 vaccines from Pfizer (PFE) and BioNTech (BNTX), and Moderna (MRNA). Reference Link

ShowHide Related Items >><<
SPX S&P 500
/

+

PFE Pfizer
$37.16 /

+0.01 (+0.03%)

MRNA Moderna
$160.10 /

+10.62 (+7.10%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

BNTX BioNTech
$132.52 /

+3.11 (+2.40%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/13/21 Goldman Sachs
J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
PFE Pfizer
$37.16 /

+0.01 (+0.03%)

04/09/21
Pfizer to host conference call
04/06/21 RBC Capital
Pfizer transferred with a Sector Perform at RBC Capital
BNTX BioNTech
$132.52 /

+3.11 (+2.40%)

02/23/21 B. Riley
B. Riley remains 'aggressive' buyer of Novavax after updated FDA guidance
02/01/21 SVB Leerink
Moderna price target raised to $80 from $69 at SVB Leerink
01/29/21 Piper Sandler
Moderna, Pfizer keep Covid vaccine competitive advantage, says Piper Sandler
01/14/21 Morgan Stanley
80%+ efficacy from J&J vaccine would be 'compelling,' says Morgan Stanley
MRNA Moderna
$160.10 /

+10.62 (+7.10%)

04/13/21 Piper Sandler
Piper reiterates $208 target on Moderna after J&J Covid vaccine pause
04/07/21 Jefferies
Catalent pact with Moderna removes potential overhang, says Jefferies
03/15/21 Piper Sandler
Piper Sandler bullish on Moderna as first subject vaccinated in '1283 study
SPX S&P 500
/

+

03/15/21 Morgan Stanley
Morgan Stanley equity strategist downgrades small cap stocks
03/12/21
On The Fly: Weekly technical notes for S&P 500
01/07/21 Credit Suisse
Credit Suisse raises 2021 S&P 500 target to 4,200, sees 12% upside
11/09/20 JPMorgan
JPMorgan sees S&P 500 hitting 4,000 by early next year
SPY SPDR S&P 500 ETF Trust
$411.49 /

-1.34 (-0.32%)

SPX S&P 500
/

+

PFE Pfizer
$37.16 /

+0.01 (+0.03%)

MRNA Moderna
$160.10 /

+10.62 (+7.10%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

  • 23
    Jul
  • 19
    May
SPX S&P 500
/

+

PFE Pfizer
$37.16 /

+0.01 (+0.03%)

MRNA Moderna
$160.10 /

+10.62 (+7.10%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

BNTX BioNTech
$132.52 /

+3.11 (+2.40%)

PFE Pfizer
$37.16 /

+0.01 (+0.03%)

MRNA Moderna
$160.10 /

+10.62 (+7.10%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

BNTX BioNTech
$132.52 /

+3.11 (+2.40%)

SPY SPDR S&P 500 ETF Trust
$411.49 /

-1.34 (-0.32%)

SPX S&P 500
/

+

PFE Pfizer
$37.16 /

+0.01 (+0.03%)

MRNA Moderna
$160.10 /

+10.62 (+7.10%)

JNJ Johnson & Johnson
$159.95 /

+0.44 (+0.28%)

BNTX BioNTech
$132.52 /

+3.11 (+2.40%)

SPY SPDR S&P 500 ETF Trust
$411.49 /

-1.34 (-0.32%)

SPX S&P 500
/

+

On The Fly
Fly Intel: Wall Street's top stories for Wednesday » 16:38
04/14/21
04/14
16:38
04/14/21
16:38
MRNA

Moderna

$160.10 /

+10.62 (+7.10%)

, GS

Goldman Sachs

$335.28 /

+7.91 (+2.42%)

, JPM

JPMorgan

$151.30 /

-2.81 (-1.82%)

, WFC

Wells Fargo

$42.01 /

+2.25 (+5.66%)

, COIN

Coinbase

$327.60 /

-53.37 (-14.01%)

, AAL

American Airlines

$22.37 /

-0.19 (-0.84%)

, JBLU

JetBlue

$20.83 /

+0.055 (+0.26%)

, TV

Televisa

$12.49 /

+2.37 (+23.42%)

, GALT

Galectin Therapeutics

$2.35 /

+0.18 (+8.29%)

, FTFT

Future FinTech

$4.19 /

-0.79 (-15.86%)

, SFIX

Stitch Fix

$46.86 /

-2.63 (-5.31%)

, BBBY

Bed Bath & Beyond

$24.52 /

-3.375 (-12.10%)

The major averages had a…

ShowHide Related Items >><<
WFC Wells Fargo
$42.01 /

+2.25 (+5.66%)

TV Televisa
$12.49 /

+2.37 (+23.42%)

SFIX Stitch Fix
$46.86 /

-2.63 (-5.31%)

MRNA Moderna
$160.10 /

+10.62 (+7.10%)

JPM JPMorgan
$151.30 /

-2.81 (-1.82%)

JBLU JetBlue
$20.83 /

+0.055 (+0.26%)

GS Goldman Sachs
$335.28 /

+7.91 (+2.42%)

GALT Galectin Therapeutics
$2.35 /

+0.18 (+8.29%)

FTFT Future FinTech
$4.19 /

-0.79 (-15.86%)

COIN Coinbase
$327.60 /

-53.37 (-14.01%)

BBBY Bed Bath & Beyond
$24.52 /

-3.375 (-12.10%)

AAL American Airlines
$22.37 /

-0.19 (-0.84%)

MRNA Moderna
$160.10 /

+10.62 (+7.10%)

04/15/21 Piper Sandler
Moderna price target raised to $234 from $208 at Piper Sandler
04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 Piper Sandler
Piper reiterates $208 target on Moderna after J&J Covid vaccine pause
04/07/21 Jefferies
Catalent pact with Moderna removes potential overhang, says Jefferies
GS Goldman Sachs
$335.28 /

+7.91 (+2.42%)

04/15/21 Barclays
Goldman Sachs price target raised to $437 from $420 at Barclays
04/15/21 RBC Capital
Goldman Sachs price target raised to $370 from $319 at RBC Capital
04/15/21 Piper Sandler
Goldman Sachs price target raised to $385 from $365 at Piper Sandler
04/14/21 Wells Fargo
Goldman Sachs price target raised to $385 from $360 at Wells Fargo
JPM JPMorgan
$151.30 /

-2.81 (-1.82%)

04/15/21 RBC Capital
JPMorgan price target raised to $160 from $150 at RBC Capital
04/15/21 Piper Sandler
JPMorgan price target raised to $182 from $170 at Piper Sandler
04/14/21 Wells Fargo
JPMorgan price target raised to $190 from $185 at Wells Fargo
04/09/21 Jefferies
JPMorgan price target raised to $177 from $157 at Jefferies
WFC Wells Fargo
$42.01 /

+2.25 (+5.66%)

04/15/21 Raymond James
Wells Fargo price target raised to $50 from $42 at Raymond James
04/15/21 BMO Capital
Wells Fargo price target raised to $43 from $40 at BMO Capital
04/15/21 Barclays
Wells Fargo price target raised to $46 from $42 at Barclays
04/15/21 Baird
Wells Fargo price target raised to $46 from $41 at Baird
COIN Coinbase
$327.60 /

-53.37 (-14.01%)

04/15/21 BTIG
Coinbase initiated with a Buy at BTIG
04/13/21
Fly Intel: Top five analyst initiations
04/13/21 MoffettNathanson
Coinbase initiated with a Buy at MoffettNathanson
04/07/21 JMP Securities
Coinbase report shows 'substantial business momentum,' says JMP Securities
AAL American Airlines
$22.37 /

-0.19 (-0.84%)

04/15/21 Barclays
American Airlines price target raised to $18 from $11 at Barclays
04/06/21 Morgan Stanley
American Airlines initiated with an Underweight at Morgan Stanley
03/30/21
Fly Intel: Top five analyst upgrades
03/30/21 Jefferies
Jefferies upgrades American Airlines to Hold on outperformance potential
JBLU JetBlue
$20.83 /

+0.055 (+0.26%)

04/15/21 Barclays
JetBlue price target raised to $20 from $14 at Barclays
04/14/21
Fly Intel: Top five analyst upgrades
04/14/21 JPMorgan
JPMorgan double upgrades JetBlue with $25 target on positive risk/reward
04/14/21 JPMorgan
JetBlue upgraded to Overweight from Underweight at JPMorgan
TV Televisa
$12.49 /

+2.37 (+23.42%)

04/15/21 Barclays
Televisa price target raised to $11 from $7.50 at Barclays
03/17/21 BBVA
Televisa upgraded to Outperform from Market Perform at BBVA
12/15/20 Morgan Stanley
Televisa downgraded to Equal Weight following rally at Morgan Stanley
12/15/20 Morgan Stanley
Televisa downgraded to Equal Weight from Overweight at Morgan Stanley
GALT Galectin Therapeutics
$2.35 /

+0.18 (+8.29%)

FTFT Future FinTech
$4.19 /

-0.79 (-15.86%)

SFIX Stitch Fix
$46.86 /

-2.63 (-5.31%)

04/05/21 Evercore ISI
Stitch Fix initiated with an Outperform at Evercore ISI
03/09/21
Fly Intel: Top five analyst downgrades
03/09/21 Canaccord
Stitch Fix price target lowered to $68 from $72 at Canaccord
03/09/21 KeyBanc
Stitch Fix price target lowered to $75 from $95 at KeyBanc
BBBY Bed Bath & Beyond
$24.52 /

-3.375 (-12.10%)

04/14/21 Wells Fargo
Bed Bath & Beyond continues to cede market share, says Wells Fargo
02/11/21
Fly Intel: Top five analyst upgrades
02/11/21 BofA
Bed Bath & Beyond upgraded to Buy after pullback at BofA
02/11/21 BofA
Bed Bath & Beyond upgraded to Buy from Neutral at BofA
WFC Wells Fargo
$42.01 /

+2.25 (+5.66%)

SFIX Stitch Fix
$46.86 /

-2.63 (-5.31%)

MRNA Moderna
$160.10 /

+10.62 (+7.10%)

JPM JPMorgan
$151.30 /

-2.81 (-1.82%)

JBLU JetBlue
$20.83 /

+0.055 (+0.26%)

GS Goldman Sachs
$335.28 /

+7.91 (+2.42%)

GALT Galectin Therapeutics
$2.35 /

+0.18 (+8.29%)

COIN Coinbase
$327.60 /

-53.37 (-14.01%)

BBBY Bed Bath & Beyond
$24.52 /

-3.375 (-12.10%)

AAL American Airlines
$22.37 /

-0.19 (-0.84%)

  • 14
    Apr
  • 02
    Dec
  • 10
    Nov
  • 23
    Jun
  • 19
    May
WFC Wells Fargo
$42.01 /

+2.25 (+5.66%)

TV Televisa
$12.49 /

+2.37 (+23.42%)

MRNA Moderna
$160.10 /

+10.62 (+7.10%)

JPM JPMorgan
$151.30 /

-2.81 (-1.82%)

JBLU JetBlue
$20.83 /

+0.055 (+0.26%)

GS Goldman Sachs
$335.28 /

+7.91 (+2.42%)

FTFT Future FinTech
$4.19 /

-0.79 (-15.86%)

COIN Coinbase
$327.60 /

-53.37 (-14.01%)

BBBY Bed Bath & Beyond
$24.52 /

-3.375 (-12.10%)

AAL American Airlines
$22.37 /

-0.19 (-0.84%)

MRNA Moderna
$160.10 /

+10.62 (+7.10%)

JPM JPMorgan
$151.30 /

-2.81 (-1.82%)

JBLU JetBlue
$20.83 /

+0.055 (+0.26%)

GS Goldman Sachs
$335.28 /

+7.91 (+2.42%)

FTFT Future FinTech
$4.19 /

-0.79 (-15.86%)

COIN Coinbase
$327.60 /

-53.37 (-14.01%)

BBBY Bed Bath & Beyond
$24.52 /

-3.375 (-12.10%)

AAL American Airlines
$22.37 /

-0.19 (-0.84%)

WFC Wells Fargo
$42.01 /

+2.25 (+5.66%)

SFIX Stitch Fix
$46.86 /

-2.63 (-5.31%)

MRNA Moderna
$160.10 /

+10.62 (+7.10%)

JPM JPMorgan
$151.30 /

-2.81 (-1.82%)

JBLU JetBlue
$20.83 /

+0.055 (+0.26%)

GS Goldman Sachs
$335.28 /

+7.91 (+2.42%)

FTFT Future FinTech
$4.19 /

-0.79 (-15.86%)

BBBY Bed Bath & Beyond
$24.52 /

-3.375 (-12.10%)

AAL American Airlines
$22.37 /

-0.19 (-0.84%)

Periodicals
Moderna discussing COVID vaccine manufacturing with Nexus, Reuters reports » 15:43
04/14/21
04/14
15:43
04/14/21
15:43
MRNA

Moderna

$158.44 /

+8.96 (+5.99%)

, JNJ

Johnson & Johnson

$159.89 /

+0.38 (+0.24%)

Moderna (MRNA), looking…

Moderna (MRNA), looking to boost production of its COVID-19 vaccine, met with Nexus Pharmaceuticals to discuss manufacturing the shot at the company's new plant in Wisconsin, which has the capacity to process and fill 30M doses a month, Reuters' Nandita Bose reports, citing sources familiar with the matter. Senior White House and administration officials, including David Kessler, chief science officer for COVID response and Tim Manning, COVID-19 supply coordinator, have facilitated introductions and discussions between Nexus, Moderna and Johnson & Johnson (JNJ), according to two sources. Reference Link

ShowHide Related Items >><<
MRNA Moderna
$158.44 /

+8.96 (+5.99%)

JNJ Johnson & Johnson
$159.89 /

+0.38 (+0.24%)

MRNA Moderna
$158.44 /

+8.96 (+5.99%)

04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 Piper Sandler
Piper reiterates $208 target on Moderna after J&J Covid vaccine pause
04/07/21 Jefferies
Catalent pact with Moderna removes potential overhang, says Jefferies
03/15/21 Piper Sandler
Piper Sandler bullish on Moderna as first subject vaccinated in '1283 study
JNJ Johnson & Johnson
$159.89 /

+0.38 (+0.24%)

04/14/21 Guggenheim
Emergent BioSolutions price target lowered to $110 from $130 at Guggenheim
04/13/21 Goldman Sachs
J&J vaccine had numerical blood clot imbalance in trial, says Goldman Sachs
04/13/21 JPMorgan
Vaccine pause 'incremental negative' for J&J, says JPMorgan
MRNA Moderna
$158.44 /

+8.96 (+5.99%)

JNJ Johnson & Johnson
$159.89 /

+0.38 (+0.24%)

  • 19
    May
MRNA Moderna
$158.44 /

+8.96 (+5.99%)

JNJ Johnson & Johnson
$159.89 /

+0.38 (+0.24%)

MRNA Moderna
$158.44 /

+8.96 (+5.99%)

JNJ Johnson & Johnson
$159.89 /

+0.38 (+0.24%)

MRNA Moderna
$158.44 /

+8.96 (+5.99%)

JNJ Johnson & Johnson
$159.89 /

+0.38 (+0.24%)

Periodicals
Moderna talking with Nexus to boost vaccine production, Reuters reports  15:39
04/14/21
04/14
15:39
04/14/21
15:39
MRNA

Moderna

$158.30 /

+8.82 (+5.90%)

 
ShowHide Related Items >><<
MRNA Moderna
$158.30 /

+8.82 (+5.90%)

MRNA Moderna
$158.30 /

+8.82 (+5.90%)

04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 Piper Sandler
Piper reiterates $208 target on Moderna after J&J Covid vaccine pause
04/07/21 Jefferies
Catalent pact with Moderna removes potential overhang, says Jefferies
03/15/21 Piper Sandler
Piper Sandler bullish on Moderna as first subject vaccinated in '1283 study
MRNA Moderna
$158.30 /

+8.82 (+5.90%)

  • 19
    May
MRNA Moderna
$158.30 /

+8.82 (+5.90%)

MRNA Moderna
$158.30 /

+8.82 (+5.90%)

MRNA Moderna
$158.30 /

+8.82 (+5.90%)

On The Fly
Fly Intel: Wall Street's top stories at midday » 12:14
04/14/21
04/14
12:14
04/14/21
12:14
MRNA

Moderna

$156.74 /

+7.26 (+4.86%)

, JPM

JPMorgan

$153.35 /

-0.76 (-0.49%)

, WFC

Wells Fargo

$42.14 /

+2.375 (+5.97%)

, GS

Goldman Sachs

$343.02 /

+15.65 (+4.78%)

, COIN

Coinbase

$0.00 /

+ (+0.00%)

, BBBY

Bed Bath & Beyond

$25.18 /

-2.71 (-9.72%)

, TV

Televisa

$12.20 /

+2.08 (+20.55%)

, GALT

Galectin Therapeutics

$2.38 /

+0.21 (+9.68%)

, FTFT

Future FinTech

$4.45 /

-0.535 (-10.74%)

, SFIX

Stitch Fix

$47.25 /

-2.24 (-4.53%)

The major averages are…

ShowHide Related Items >><<
WFC Wells Fargo
$42.14 /

+2.375 (+5.97%)

TV Televisa
$12.20 /

+2.08 (+20.55%)

SFIX Stitch Fix
$47.25 /

-2.24 (-4.53%)

MRNA Moderna
$156.74 /

+7.26 (+4.86%)

JPM JPMorgan
$153.35 /

-0.76 (-0.49%)

GS Goldman Sachs
$343.02 /

+15.65 (+4.78%)

GALT Galectin Therapeutics
$2.38 /

+0.21 (+9.68%)

FTFT Future FinTech
$4.45 /

-0.535 (-10.74%)

COIN Coinbase
$0.00 /

+ (+0.00%)

BBBY Bed Bath & Beyond
$25.18 /

-2.71 (-9.72%)

MRNA Moderna
$156.74 /

+7.26 (+4.86%)

04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 Piper Sandler
Piper reiterates $208 target on Moderna after J&J Covid vaccine pause
04/07/21 Jefferies
Catalent pact with Moderna removes potential overhang, says Jefferies
03/15/21 Piper Sandler
Piper Sandler bullish on Moderna as first subject vaccinated in '1283 study
JPM JPMorgan
$153.35 /

-0.76 (-0.49%)

04/09/21 Jefferies
JPMorgan price target raised to $177 from $157 at Jefferies
04/07/21 Barclays
JPMorgan price target raised to $187 from $172 at Barclays
04/05/21 Cowen
Risk to mortgage servicers rises as CFPB proposes foreclosure policy, says Cowen
04/01/21 Deutsche Bank
JPMorgan price target raised to $175 from $142 at Deutsche Bank
WFC Wells Fargo
$42.14 /

+2.375 (+5.97%)

04/09/21 Jefferies
Wells Fargo price target raised to $45 from $37 at Jefferies
04/07/21 Barclays
Wells Fargo price target raised to $42 from $36 at Barclays
04/01/21 Deutsche Bank
Wells Fargo price target raised to $45 from $35 at Deutsche Bank
GS Goldman Sachs
$343.02 /

+15.65 (+4.78%)

04/14/21 JMP Securities
JMP reiterates Outperform rating, $400 target on Goldman after 'blockbuster' Q1
04/09/21 JMP Securities
Goldman Sachs price target raised to $400 from $338 at JMP Securities
04/08/21 Citi
Goldman Sachs price target raised to $390 from $370 at Citi
04/07/21 Barclays
Goldman Sachs price target raised to $420 from $392 at Barclays
COIN Coinbase
$0.00 /

+ (+0.00%)

04/13/21
Fly Intel: Top five analyst initiations
04/13/21 MoffettNathanson
Coinbase initiated with a Buy at MoffettNathanson
04/07/21 JMP Securities
Coinbase report shows 'substantial business momentum,' says JMP Securities
03/03/21
Fly Intel: Top five analyst initiations
BBBY Bed Bath & Beyond
$25.18 /

-2.71 (-9.72%)

02/11/21
Fly Intel: Top five analyst upgrades
02/11/21 BofA
Bed Bath & Beyond upgraded to Buy after pullback at BofA
02/11/21 BofA
Bed Bath & Beyond upgraded to Buy from Neutral at BofA
02/03/21 Odeon Capital
Odeon sees nearly 50% upside in Bed Bath & Beyond, upgrades back to Buy
TV Televisa
$12.20 /

+2.08 (+20.55%)

03/17/21 BBVA
Televisa upgraded to Outperform from Market Perform at BBVA
12/15/20 Morgan Stanley
Televisa downgraded to Equal Weight following rally at Morgan Stanley
12/15/20 Morgan Stanley
Televisa downgraded to Equal Weight from Overweight at Morgan Stanley
05/12/20 Credit Suisse
Televisa upgraded to Outperform from Neutral at Credit Suisse
GALT Galectin Therapeutics
$2.38 /

+0.21 (+9.68%)

FTFT Future FinTech
$4.45 /

-0.535 (-10.74%)

SFIX Stitch Fix
$47.25 /

-2.24 (-4.53%)

04/05/21 Evercore ISI
Stitch Fix initiated with an Outperform at Evercore ISI
03/09/21
Fly Intel: Top five analyst downgrades
03/09/21 Canaccord
Stitch Fix price target lowered to $68 from $72 at Canaccord
03/09/21 KeyBanc
Stitch Fix price target lowered to $75 from $95 at KeyBanc
WFC Wells Fargo
$42.14 /

+2.375 (+5.97%)

SFIX Stitch Fix
$47.25 /

-2.24 (-4.53%)

MRNA Moderna
$156.74 /

+7.26 (+4.86%)

JPM JPMorgan
$153.35 /

-0.76 (-0.49%)

GS Goldman Sachs
$343.02 /

+15.65 (+4.78%)

GALT Galectin Therapeutics
$2.38 /

+0.21 (+9.68%)

COIN Coinbase
$0.00 /

+ (+0.00%)

BBBY Bed Bath & Beyond
$25.18 /

-2.71 (-9.72%)

  • 14
    Apr
  • 19
    May
WFC Wells Fargo
$42.14 /

+2.375 (+5.97%)

TV Televisa
$12.20 /

+2.08 (+20.55%)

MRNA Moderna
$156.74 /

+7.26 (+4.86%)

JPM JPMorgan
$153.35 /

-0.76 (-0.49%)

GS Goldman Sachs
$343.02 /

+15.65 (+4.78%)

FTFT Future FinTech
$4.45 /

-0.535 (-10.74%)

COIN Coinbase
$0.00 /

+ (+0.00%)

BBBY Bed Bath & Beyond
$25.18 /

-2.71 (-9.72%)

WFC Wells Fargo
$42.14 /

+2.375 (+5.97%)

SFIX Stitch Fix
$47.25 /

-2.24 (-4.53%)

MRNA Moderna
$156.74 /

+7.26 (+4.86%)

JPM JPMorgan
$153.35 /

-0.76 (-0.49%)

GS Goldman Sachs
$343.02 /

+15.65 (+4.78%)

FTFT Future FinTech
$4.45 /

-0.535 (-10.74%)

COIN Coinbase
$0.00 /

+ (+0.00%)

BBBY Bed Bath & Beyond
$25.18 /

-2.71 (-9.72%)

WFC Wells Fargo
$42.14 /

+2.375 (+5.97%)

SFIX Stitch Fix
$47.25 /

-2.24 (-4.53%)

MRNA Moderna
$156.74 /

+7.26 (+4.86%)

JPM JPMorgan
$153.35 /

-0.76 (-0.49%)

GS Goldman Sachs
$343.02 /

+15.65 (+4.78%)

FTFT Future FinTech
$4.45 /

-0.535 (-10.74%)

BBBY Bed Bath & Beyond
$25.18 /

-2.71 (-9.72%)

Options
Moderna call volume above normal and directionally bullish » 10:45
04/14/21
04/14
10:45
04/14/21
10:45
MRNA

Moderna

$155.00 /

+5.52 (+3.69%)

Bullish option flow…

Bullish option flow detected in Moderna with 28,735 calls trading, 3x expected, and implied vol increasing almost 7 points to 66.90%. Apr-21 155 calls and Apr-21 160 calls are the most active options, with total volume in those strikes near 5,200 contracts. The Put/Call Ratio is 0.27. Earnings are expected on May 5th.

ShowHide Related Items >><<
MRNA Moderna
$155.00 /

+5.52 (+3.69%)

MRNA Moderna
$155.00 /

+5.52 (+3.69%)

04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 Piper Sandler
Piper reiterates $208 target on Moderna after J&J Covid vaccine pause
04/07/21 Jefferies
Catalent pact with Moderna removes potential overhang, says Jefferies
03/15/21 Piper Sandler
Piper Sandler bullish on Moderna as first subject vaccinated in '1283 study
MRNA Moderna
$155.00 /

+5.52 (+3.69%)

  • 19
    May
MRNA Moderna
$155.00 /

+5.52 (+3.69%)

MRNA Moderna
$155.00 /

+5.52 (+3.69%)

MRNA Moderna
$155.00 /

+5.52 (+3.69%)

Hot Stocks
Moderna says COVID-19 vaccine seen 90% effective against all cases at six months » 09:24
04/14/21
04/14
09:24
04/14/21
09:24
MRNA

Moderna

$149.63 /

+10.34 (+7.42%)

Last night, Moderna…

Last night, Moderna shared an update on the Phase 3 COVE study of the Moderna COVID-19 Vaccine, mRNA-1273. "An updated review of adjudicated cases has identified over 900 cases of COVID-19 in the COVE study as of April 9th, including over 100 cases of severe COVID-19, as defined in the protocol, with a median follow-up of approximately 6 months post dose 2. Vaccine efficacy starting two weeks following the second dose and based on the updated adjudicated cases remains consistent with prior updates, including greater than 90% against all cases of COVID-19, and greater than 95% against severe cases of COVID-19. As of April 13, all placebo participants have been offered the Moderna COVID-19 Vaccine and 98% of those have received the vaccine. The COVE study is ongoing and reported results remain preliminary. Throughout the year, Moderna will be sharing updated data from the Phase 3 COVE study including efficacy against asymptomatic infection, genotyping data, additional antibody persistence data and information regarding potential correlates of protection," Moderna stated. In addition, Moderna said that in the fourth quarter of 2020, the company delivered approximately 17M doses to the U.S. government. For the first quarter of 2021, the company delivered approximately 88M doses to the U.S. government and approximately 14M doses to other customers. Through April 12, 2021, Moderna cumulatively delivered approximately 132M doses globally, including approximately 117M doses to the U.S. government and approximately 15M doses delivered from Moderna's ex-U.S. supply chain. The company said it remains on track to deliver the second 100M doses to the U.S. government by end of May 2021 followed by another 100M additional doses by end of July 2021. "The ex-U.S. supply chain was established approximately one quarter behind the U.S. supply chain and continues to ramp up," Moderna added.

ShowHide Related Items >><<
MRNA Moderna
$149.63 /

+10.34 (+7.42%)

MRNA Moderna
$149.63 /

+10.34 (+7.42%)

04/13/21 Morgan Stanley
Morgan Stanley says J&J news could improve 2022 outlook for mRNA vaccine makers
04/13/21 Piper Sandler
Piper reiterates $208 target on Moderna after J&J Covid vaccine pause
04/07/21 Jefferies
Catalent pact with Moderna removes potential overhang, says Jefferies
03/15/21 Piper Sandler
Piper Sandler bullish on Moderna as first subject vaccinated in '1283 study
MRNA Moderna
$149.63 /

+10.34 (+7.42%)

  • 19
    May
MRNA Moderna
$149.63 /

+10.34 (+7.42%)

MRNA Moderna
$149.63 /

+10.34 (+7.42%)

MRNA Moderna
$149.63 /

+10.34 (+7.42%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.